Limkato (anbalcabtagene autoleucel)
ApprovedTreatment for adults with relapsed or refractory large B-cell lymphoma, approved in Korea in April 2026.
FROM PUBLIC EVENTS · 2026-11-15
Commercial · sales Approved for Korea's first in-house CAR-T therapy, it is starting commercialisation at major hospitals. Also seen: Early clinical · first deals
Roles often seen at this stageManufacturing & MSAT · Sales & marketing · Medical & MSL
A CAR-T cell-therapy developer that received approval for the first CAR-T therapy developed in-house by a Korean company.
Treatment for adults with relapsed or refractory large B-cell lymphoma, approved in Korea in April 2026.
Received Korean marketing approval for the CAR-T therapy Limkato.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.